On January 5, 2022 Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, reported that Frances L. Johnson MD, Chief Executive Officer and Co-Founder of Viewpoint, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022 (Press release, Viewpoint Molecular Targeting, JAN 5, 2022, https://viewpointmt.com/viewpoint-molecular-targeting-to-present-at-the-h-c-wainwright-bioconnect-conference/ [SID1234598309]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A video webcast of the presentation will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be accessible on the Company’s website (viewpointmt.com). The webcast replay will be archived for 90 days following the event.